Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SLGL 
Sol Gel Technologies Ltd (SLGL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: SLGL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4
1 Year Target Price $4
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 47.38% | Avg. Invested days 27 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 113.10M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 1 | Beta 1.3 | 52 Weeks Range 4.01 - 52.26 | Updated Date 10/17/2025 |
52 Weeks Range 4.01 - 52.26 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.22 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -14.25% | Operating Margin (TTM) 65.06% |
Management Effectiveness
Return on Assets (TTM) -7.33% | Return on Equity (TTM) -10.21% |
Valuation
Trailing PE - | Forward PE 9.34 | Enterprise Value 59075716 | Price to Sales(TTM) 4.73 |
Enterprise Value 59075716 | Price to Sales(TTM) 4.73 | ||
Enterprise Value to Revenue 2.47 | Enterprise Value to EBITDA 0.24 | Shares Outstanding 2785787 | Shares Floating 549970 |
Shares Outstanding 2785787 | Shares Floating 549970 | ||
Percent Insiders 70 | Percent Institutions 25.02 |
Upturn AI SWOT
Sol Gel Technologies Ltd
Company Overview
History and Background
Sol-Gel Technologies Ltd. is a dermatology company that develops and commercializes topical generic and proprietary pharmaceutical products utilizing its silica-based microencapsulation technology. Founded in 2003, it focuses on creating treatments for acne, rosacea, and other skin conditions.
Core Business Areas
- Dermatology Products: Development and commercialization of topical medications for skin conditions, focusing on acne and rosacea.
- Silica-Based Microencapsulation Technology: Application of its proprietary technology to improve the efficacy and tolerability of topical drugs.
Leadership and Structure
The leadership team includes a CEO, CFO, and Chief Medical Officer, with a board of directors overseeing the company's strategy and operations. The company has departments focused on research and development, manufacturing, and commercialization.
Top Products and Market Share
Key Offerings
- EPSOLAY: Topical benzoyl peroxide cream for rosacea. Competitors include other topical rosacea treatments and oral medications. Market share data not reliably available. Limited data available. Company Reported revenue of $1.7 million for FY 2024.
- TWYNEO: Topical tretinoin and benzoyl peroxide cream for acne. Competitors include other topical acne treatments. Market share data not reliably available. Limited data available.Company Reported revenue of $11.4 million for FY 2024.
Market Dynamics
Industry Overview
The dermatology market is characterized by increasing demand for effective and convenient treatments for common skin conditions. Competition is intense, with established pharmaceutical companies and emerging biotech firms developing innovative products.
Positioning
Sol-Gel Technologies positions itself as a specialized dermatology company with a focus on innovative topical formulations. Its competitive advantage lies in its silica-based microencapsulation technology, which aims to improve drug delivery and reduce side effects.
Total Addressable Market (TAM)
The global dermatology market is estimated to be in the tens of billions of dollars. Sol-Gel Technologies targets specific segments within this market, particularly acne and rosacea. Their TAM is limited by their existing product portfolio and geographic focus.
Upturn SWOT Analysis
Strengths
- Proprietary silica-based microencapsulation technology
- Approved products for acne and rosacea
- Focus on improving drug delivery and tolerability
- Experienced management team in dermatology
Weaknesses
- Reliance on a limited number of products
- Potential dependence on collaborations or partnerships for commercialization
- High research and development costs
- Relatively small market capitalization
Opportunities
- Expanding product pipeline through internal development or acquisitions
- Entering new geographic markets
- Collaborating with larger pharmaceutical companies
- Developing new formulations for other skin conditions
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Patent challenges or infringements
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- GALDERMA (GALDY.SW)
- BAXALTA (now part of Takeda, TAK)
- LAVRIO (LVRO)
Competitive Landscape
Sol-Gel Technologies competes with both large pharmaceutical companies and smaller biotech firms in the dermatology market. Its competitive advantage lies in its silica-based microencapsulation technology. Smaller market share and a very niche market will be a hurdle for Sol-Gel.
Growth Trajectory and Initiatives
Historical Growth: The company's historical growth has been driven by the approval and commercialization of its acne and rosacea products.
Future Projections: Future growth depends on the successful development and commercialization of new products, including those in its pipeline. Analyst estimates suggest continued revenue growth in the coming years, but profitability remains uncertain.
Recent Initiatives: Recent initiatives include expanding its sales force, initiating new clinical trials, and exploring strategic partnerships.
Summary
Sol-Gel Technologies is a dermatology company with proprietary drug delivery technology and approved products for acne and rosacea. While the company has grown revenue recently, it still struggles with net losses, and significant debt. It faces strong competition from established players in the dermatology market. Growth is expected to increase, but the path to profitability is not guaranteed.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Press Releases
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data is based on limited data and estimates. Investment decisions should be based on your own due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sol Gel Technologies Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2018-01-23 | CEO & Executive Chairman Mr. Moshe Arkin | ||
Sector Healthcare | Industry Biotechnology | Full time employees 34 | Website https://www.sol-gel.com |
Full time employees 34 | Website https://www.sol-gel.com | ||
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.